Immunogenicity of Haemophilus influenzae Type b Conjugate Vaccines in Korean Infants: A Meta-analysis

被引:8
作者
Lee, Hyunju [1 ]
Hahn, Seokyung [2 ]
Lee, Hoan Jong [3 ]
Kim, Kyung-Hyo [1 ]
机构
[1] Ewha Womans Univ, Sch Med, Dept Pediat, Seoul 158710, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Med, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul, South Korea
关键词
Haemophilus influenzae type b; Vaccines; Immunity; Meta-analysis; CAPSULAR POLYSACCHARIDE; SERUM ANTIBODIES; RANDOMIZED-TRIAL; PROTECTIVE LEVEL; VACCINATION; EFFICACY; IMMUNIZATION; CHILDREN;
D O I
10.3346/jkms.2010.25.1.90
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A meta-analysis was performed on the immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines after 2 (2 and 4 months) and 3 doses (2, 4, and 6 months) in Korean infants. A database search of MEDLINE, KoreaMed, and Korean Medical Database was done. The primary outcome measure was the proportion of infants with anti-polyribosylribitol phosphate (PRP) concentrations >= 1.0 mu g/mL. Eight studies including eleven trials were retrieved. One trial reported on the diphtheria toxoid conjugate vaccine (PRP-D) and 2 trials each on the mutant diphtheria toxin (PRP-CRM) and Neisseria meningitidis outer-membrane protein (PRP-OMP) conjugate vaccine. Heterogeneity in study designs between trials on PRP-CRM was noted and one trial reported on a monovalent and another on a combination PRP-OMP vaccine. Thus, a meta-analysis was conducted only on the tetanus toxoid conjugate vaccine (PRP-T). After a primary series of 2 doses and 3 doses, 80.6% (95% confidence interval [CI]; 76.0-85.1%) and 95.7% (95% CI; 94.0-98.0%) of infants achieved an antibody level >= 1.0 mu g/mL, respectively. The immunogenic response to the PRP-T vaccine was acceptable after a primary series of 3 doses and also 2 doses. A reduced number of doses as a primary series could be carefully considered in Korean infants.
引用
收藏
页码:90 / 96
页数:7
相关论文
共 30 条
  • [1] ANDERSON P, 1984, J INFECT DIS, V149, P1034, DOI 10.1093/infdis/149.6.1034
  • [2] *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P234
  • [3] CHOI SY, 1999, J KOREAN PEDIAT SOC, V42, P771
  • [4] CHUNG EH, 2006, KOREAN J PEDIAT INFE, V13, P163
  • [5] CHUNG EH, 2003, KOREAN J PEDIAT INFE, V10, P71
  • [6] COMPARATIVE TRIAL IN INFANTS OF 4 CONJUGATE HAEMOPHILUS-INFLUENZAE TYPE-B VACCINES
    DECKER, MD
    EDWARDS, KM
    BRADLEY, R
    PALMER, P
    [J]. JOURNAL OF PEDIATRICS, 1992, 120 (02) : 184 - 189
  • [7] METAANALYSIS IN CLINICAL-TRIALS
    DERSIMONIAN, R
    LAIRD, N
    [J]. CONTROLLED CLINICAL TRIALS, 1986, 7 (03): : 177 - 188
  • [8] A RANDOMIZED, PROSPECTIVE FIELD TRIAL OF A CONJUGATE VACCINE IN THE PROTECTION OF INFANTS AND YOUNG-CHILDREN AGAINST INVASIVE HAEMOPHILUS-INFLUENZAE TYPE-B DISEASE
    ESKOLA, J
    KAYHTY, H
    TAKALA, AK
    PELTOLA, H
    RONNBERG, PR
    KELA, E
    PEKKANEN, E
    MCVERRY, PH
    MAKELA, PH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (20) : 1381 - 1387
  • [9] Assessing efficacy of Haemophilus influenzae type b combination vaccines
    Granoff, DM
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 : S278 - S287
  • [10] Haemophilus influenzae type b conjugate vaccines:: a review of efficacy data
    Heath, PT
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (09) : S117 - S122